• No results found

GnRH antagonists

Optimal usage of the GnRH antagonists: a review of the literature

Optimal usage of the GnRH antagonists: a review of the literature

... of GnRH antagonists for the inhibition of premature LH surges in women undergoing controlled ovarian stimula- tion are hypersensitivity to GnRH antagonists or preg- nancy ...[112]. GnRH ...

13

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial

... a GnRH antagonist to lower estradiol levels, as well as the ongo- ing pregnancy rates, were also similar when protocols B (stimulation in follicular phase) and C (stimulation on luteal phase) were compared with ...

7

Strategies for Pituitary Down-regulation to Optimize IVF/ICSI Outcome in Poor Ovarian Responders

Strategies for Pituitary Down-regulation to Optimize IVF/ICSI Outcome in Poor Ovarian Responders

... using GnRH-antgonist for ovarian stimulation in poor responders, no differ- ences in clinical outcomes were found, except a significantly higher number of cumulus-oocyte complexes in the GnRH-antagonist ...

7

Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial

Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial

... lar GnRH antagonists pretreatment for 7 days after preceding late luteal estrogen priming and before the beginning of ovarian stimulation (delayed start proto- col) with GnRH antagonists with ...

7

GnRH Antagonist Protocol: Is It Effective for Expected Poor Ovarian Responders with Tubal Factor Undergoing IVF?

GnRH Antagonist Protocol: Is It Effective for Expected Poor Ovarian Responders with Tubal Factor Undergoing IVF?

... of GnRH antagonists presented hope for POR. GnRH antagonists can induce pituitary suppression within a few hours without a “flare-up” effect, and the suppression can be released immediately ...

7

Switching from a gonadotropin releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta analysis

Switching from a gonadotropin releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta analysis

... to GnRH antagonists as treatment after PSA progression on a GnRH agonist, though a switch may be considered when testosterone levels are incompletely ...a GnRH agonist to antagonist switch at ...

16

Pregnancy outcome of “delayed start” GnRH antagonist protocol versus GnRH antagonist protocol in poor responders: A clinical trial study

Pregnancy outcome of “delayed start” GnRH antagonist protocol versus GnRH antagonist protocol in poor responders: A clinical trial study

... follicular GnRH antagonists pretreatment for 7 days after preceding late luteal estrogen priming and before the beginning of ovarian stimulation (delayed start protocol) with GnRH antagonists ...

8

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

... Several strategies have been proposed to prevent or minimize the intensity of OHSS. Cycle cancellation, withholding gonadotropins administration and postpon- ing human chorionic gonadotropin (HCG) injection till HCG ...

8

GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology

GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology

... of GnRH analo- gues, a surge in LH occurs after approximately 20% of all IVF cycles/intracytoplasmic sperm injections (ICSI) ...increased. GnRH agonists (GnRH-a) have been used in assisted ...

10

Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis

<p>Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis</p>

... that GnRH antagonists might have a less detrimental effect on CV health than GnRH agonists, 11,14,20,24 a post hoc analysis gathering data from three prospective randomized trials on 2328 patients ...

9

ART Outcomes in GnRH Antagonist Protocol (Flexible) and Long GnRH Agonist Protocol during Early Follicular Phase in Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial

ART Outcomes in GnRH Antagonist Protocol (Flexible) and Long GnRH Agonist Protocol during Early Follicular Phase in Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial

... 7). GnRH antagonists have several advantages over GnRH ...with GnRH agonist protocols ...in GnRH agonists and GnRH antagonists groups ...of GnRH antagonists ...

7

 NEW INSIGHTS INTO MOLECULAR TARGETS FOR DEPRESSION

 NEW INSIGHTS INTO MOLECULAR TARGETS FOR DEPRESSION

... adrenergic antagonists markedly potentiate the ability of antidepressants to increase extracellular levels of norepinephrine, serotonin, and dopamine, depending on the brain region examined 23 ...

7

Proteinase-activated receptors (PARs) as targets for antiplatelet therapy

Proteinase-activated receptors (PARs) as targets for antiplatelet therapy

... Strategies to inhibit PAR4 activity have been less successful than those directed towards targeting PAR1 and PAR2 activity. PAR4 is an important target as the inhibition of sustained platelet responses via thrombin- PAR4 ...

12

Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis

Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis

... The initiation of mammalian puberty and the maintenance of female reproductive cycles are events controlled by hypothalamic neurons that secrete the decapeptide gonadotropin- releasing hormone (GnRH). GnRH ...

11

GnRH I and II up-regulate MMP-26 expression through the JNK pathway in human cytotrophoblasts

GnRH I and II up-regulate MMP-26 expression through the JNK pathway in human cytotrophoblasts

... and GnRH II have been shown to regulate the expression of MMP-2, MMP-9/tissue inhibitor of metalloproteinases 1 (TIMP-1), and urokinase plasminogen activator (uPA)/plasminogen activator inhibitor (PAI) in human ...

10

Use of sequence GnRH III for philogenetic analysis of red hard lipped barb carp, green hard lipped barb carp, mangot hard lipped barb carp and beureum panon

Use of sequence GnRH III for philogenetic analysis of red hard lipped barb carp, green hard lipped barb carp, mangot hard lipped barb carp and beureum panon

... Composition of reaction amplification using PCR method consists of: 12.5 µl go taq® green master mix, 1.5 µl of GnRH III-F and 1.5 µl GnRH III-R primers, 2.0 µl DNA template and 7.5 µl nuclease free water ...

5

Gonadotropin releasing hormone receptor mRNA expression by human pituitary tumors in vitro

Gonadotropin releasing hormone receptor mRNA expression by human pituitary tumors in vitro

... An important question in the pathogenesis and regulation of human gonadotroph adenomas is whether heterogeneous gonadotropin responses to gonadotropin-releasing hormone (GnRH) are due to dysregulation of ...

9

Predictive factors for oocyte retrieval failure in controlled ovarian hyperstimulation protocols: a retrospective observational cohort study

Predictive factors for oocyte retrieval failure in controlled ovarian hyperstimulation protocols: a retrospective observational cohort study

... analysis, GnRH an- tagonist protocol (odds ratio [OR] ...with GnRH agonist long and GnRH antagonist protocols ...with GnRH agonist long protocol ...

7

GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET)

GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET)

... Several randomized clinical trials demonstrate that in IVF-ET, the combination of exogenous gonadotropin plus Gonadotropin Releasing Hormone agonist (GnRH-a), for the suppression of pituitary FSH and LH secretion, ...

8

New algorithm for OHSS prevention

New algorithm for OHSS prevention

... At the same time, the development of the vitrification procedure has improved the embryo survival rate as compared to the classical method of slow freezing [10]. Thus, considering the different modalities that the phy- ...

5

Show all 844 documents...

Related subjects